Fusaloyos

Quick links to important sections

Fusaloyos

Method of action: Throat Preparations

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Fusaloyos

Fusaloyos is a medicinal preparation whose active substance is Fusafungine, a drug characterized by both antibiotic and anti-inflammatory properties, intended specifically for localized treatment of the upper respiratory tract. It is typically positioned for the symptomatic relief of acute conditions like rhinopharyngitis.

Property Description
Active ingredient Fusafungine
Form Aerosol or Spray Solution
Pharmacological Class Topical Antibiotic / Anti-inflammatory
General Use Relief from respiratory tract irritation
Origin Natural Product (Fungal Derivative)

What is Fusafungine, the Active Ingredient in Fusaloyos?

Fusaloyos contains the single active ingredient, Fusafungine, which is classified within the category of throat preparations with antimicrobial properties. This dual pharmacological class establishes the drug not merely as an anti-infective agent but as one that is clinically recognized for modifying the local inflammatory response. The drug entity's core function is to address both the microbial component and the associated irritation often found in the upper respiratory system.


Natural Origin, Chemical Type, and Local Form

Fusafungine is chemically distinct as a cyclic depsipeptide, a natural product sourced from the cultivation of the fungus Fusarium lateritium. This biological origin is a key differentiating feature from many common synthetic antibiotics. The medicine is formulated as an aerosol or spray solution, delivered via oromucosal inhalation or nasal administration. This delivery method is crucial, as it ensures the drug is applied directly and topically onto the irritated lining of the throat and nasal passages, limiting its systemic presence.


General Therapeutic Purpose and Dual Action

The overall purpose of this medicine is to offer relief from the general discomfort associated with upper respiratory tract irritation. This relief stems from its inherent dual action, which involves an antimicrobial property to help control microorganisms and an anti-inflammatory effect to soothe associated tissue swelling and redness. This combined approach simultaneously addresses the microbial presence and the body’s localized inflammatory response, working to provide comprehensive, localized symptomatic relief from common issues like throat soreness and swelling.

What side effects are possible with Fusaloyos?

Possible Side Effects and Safety Information

The official safety documentation for Fusaloyos (Fusafungine) is characterized by the potential for allergic reactions, which range from local irritation to severe systemic events, as outlined in government regulatory reviews.


Documented Adverse Reactions

The documented adverse effects are grouped into specific System-Organ Classes primarily involving the Immune system disorders and the Respiratory, thoracic and mediastinal disorders. Local reactions at the application site may include localized discomfort, such as sneezing or a sensation of dryness in the nose or throat. Less common effects reported include pruritus (itching) or urticaria (hives).

Serious Adverse Reactions

The most significant safety concerns documented in regulatory assessments are serious allergic reactions, which are considered rare but potentially life-threatening. These include:

  • Anaphylactic shock
  • Angioedema (swelling, often of the face or throat)
  • Bronchospasm (severe airway constriction)
  • Laryngeal spasm (spasm of the vocal cords)

The frequency of these severe reactions is generally classified as Not known but their potential severity governs the official safety profile.


Population-Specific Safety Constraints

The risk profile necessitates specific constraints documented in regulatory labeling. Due to the heightened risk of serious adverse reactions, especially laryngeal spasm, the medicine is officially contraindicated in infants and children. Furthermore, individuals with a history of asthma or allergy are officially noted to be at a higher risk of experiencing severe allergic events and are restricted from use. These official safety statements define the primary limitations associated with this medicine.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory documentation for Fusaloyos (Fusafungine) provides information on documented clinical signs and the required management approach in cases of overdose, noting that experience with overdose is limited.

Documented Overdose Manifestations

Official prescribing information summarizes the reported clinical presentation associated with overdose. Manifestations include both systemic and local effects:

  • Systemic Effects: Documented signs include circulatory disorders and dizziness.
  • Local Effects: Reported local injury involves numbness in mouth, worsening of sore throat, and chemical burn of the throat.

Emergency Management and Required Action

In the event of a suspected overdose, medical attention must be sought immediately to ensure proper clinical management. Regulatory documents define the required management strategy as entirely symptomatic and supportive.

Management Procedure Regulatory Requirement
Antidote Availability No specific antidote is officially listed.
Required Action Management consists of treatment of clinical symptoms.
Observation Routine monitoring is required for patient stabilization.

Seeking emergency medical care is mandatory to facilitate the required routine monitoring and appropriate treatment of clinical symptoms for the documented manifestations, particularly for severe effects such as circulatory disorders or chemical burn of the throat.

Therapeutic Uses of Fusaloyos

What Fusaloyos Treats: Main Uses and Benefits

Fusaloyos (Fusafungine) is a product historically used for localized, supportive management within the upper respiratory tract. This historical use is associated with the management of airway infections.

The medicine is relevant in clinical settings that involve acute or unstable symptom patterns, and has been associated with conditions such as rhinopharyngitis, rhinitis, sinusitis, laryngitis, and tonsillitis. It is applied across domains where additional symptomatic support is needed.

Fusaloyos is used in areas where short-term symptom management is appropriate, supporting multiple symptom-focused domains like pharyngeal discomfort and nasal passage irritation. It helps address symptom clusters that may become intense or disruptive, including manifestations such as sore throat, painful swallowing (dysphagia), nasal obstruction, and excessive secretions.

This supportive approach may assist with maintaining functional stability and contributes to easing the overall symptom load during periods of heightened symptoms. Fusaloyos is applied in situations involving symptoms related to inflammatory or irritative states.


Quick Fact: Relief for Dual Symptomatic Discomfort (Throat and Nose)

Eligibility and Restrictions for Use

The eligibility for Fusaloyos (Fusafungine) is severely restricted by regulatory action. Due to an unfavorable benefit-risk profile related to the risk of serious allergic reactions, marketing authorizations for this medicine have been revoked in the European Union and certain other regions. This decisive action functions as an absolute contraindication for the general population in affected territories, superseding all prior restrictions.

Prior to regulatory withdrawal, official labeling strictly defined additional contraindications. These include children under 12 years of age. Use was also prohibited in patients with a known hypersensitivity to fusafungine or any excipients. Furthermore, the medicine was contraindicated in individuals with known allergic tendencies or a history of bronchospasm due to the high risk of adverse reactions.

Population Eligibility Status Official Regulatory Classification
Absolute Prohibition Contraindicated (via market revocation)
Pediatric Restriction Contraindicated in children under 12 years of age
Allergy Risk Contraindicated in allergic tendencies/bronchospasm
Pregnancy Use requires caution
Lactation Not recommended

For pregnant women, use is classified as requiring caution. The medicine is not recommended for women who are breastfeeding. Patients with hepatic or renal impairment were historically permitted use under standard labeled conditions, as regulatory documents did not specify the need for dose adjustments.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Fusaloyos (Fusafungine) is defined by the documented absence of formal interaction studies. The European regulatory documentation, which includes the Summary of Product Characteristics, formally states that no interaction studies have been performed to systematically document potential patterns with other substances.

Due to the localized delivery and limited systemic absorption of this aerosol, the overall potential for clinically significant systemic drug-drug interactions is considered low, however, no formal data exists to support this assessment.

Officially Undocumented Interaction Patterns

The lack of formal studies means the regulatory label does not specify constraints across key interaction categories.

Interaction Category Regulatory Status
Contraindicated Combinations None formally identified or listed based on drug interaction risk.
Pharmacokinetic Interactions No data on metabolic (CYP enzyme) or transporter-mediated effects are documented.
Pharmacodynamic Interactions No additive or synergistic effects with co-administered drugs are officially noted.
Food, Alcohol, or Supplements No specific interaction patterns are documented in the official prescribing information.
Administration Timing No mandatory separation rules for administration time are documented in the label.

Regulatory Conclusion

The product labeling does not list specific interacting medicines, timing requirements, or metabolic effects. The official documentation therefore contains no restrictions or prohibitions concerning co-administration that are grounded in formal interaction study data.

Mechanism of Action

How Fusaloyos Works: Dual Mechanism of Action

Fusafungine exerts a localized, dual mechanism of action on the upper respiratory mucosa. The molecule's cyclic depsipeptide structure acts as an ionophore, interacting with the cell membranes of susceptible bacteria and fungi. By facilitating cation transport, this mechanism disrupts the essential osmotic and electrical balance required for proliferation, resulting in a bacteriostatic and fungistatic effect.

Simultaneously, Fusafungine modulates the host’s local inflammatory response. It acts on activated immune cells and epithelial surfaces to suppress the release of pro-inflammatory mediators ( TNF-alpha, IL-1beta, IL-6) and reduce the expression of the adhesion molecule ICAM-1. This pathway modulation modifies the signaling cascade that typically drives tissue fluid accumulation and leukocyte transmigration. The resulting physiological consequence is decreased local vascular permeability** and a lower rate of cellular infiltration. The integration of microbial growth inhibition with the suppression of the inflammatory cascade promotes the maintenance of tissue homeostasis in the respiratory tract.

Dosage and Administration Information

How to Use Fusaloyos

Fusaloyos (Fusafungine) is administered via localized inhalation to the upper respiratory tract. The medicine is delivered as a spray solution, with each dose measured to provide 125 micrograms of fusafungine per puff. Administration involves two specific routes for direct topical application: oromucosal (mouth/throat) and nasal (nostril).


Administration Protocol

The usage protocol involves a fixed frequency and duration for the course of treatment.

Feature Adult Dosing Schedule Children (> 30 months) Dosing Schedule
Mouth/Throat (Oromucosal) 4 puffs 2 puffs
Nostrils (Nasal) 2 puffs in each nostril 1 puff in each nostril
Frequency 4 times daily 4 times daily

Procedural and Time Constraints

The overall treatment is intended for short-term use, with a duration that does not exceed 7 days. If no symptomatic improvement is observed after this seven-day period, the use of the product is discontinued.

Prior to the first administration, the spray device requires priming. This is achieved by pressing the actuator four times to ensure the proper volume is dispensed. The use of the appropriate attachment (adaptor) is used to target the nasal or oromucosal area.

Dosing is not applicable to children under 30 months of age. No dose adjustments are indicated for older adults or patients with hepatic or renal impairment.

Recent Clinical Evidence

Fusaloyos: Recent Clinical Evidence

Evidence for Use in Acute Upper Respiratory Tract Conditions

Fusaloyos was evaluated in research exploring conditions such as rhinopharyngitis (common cold), rhinitis, and acute laryngitis, which are conditions involving periods of heightened symptoms. The studies were conducted during periods of increased symptom activity and primarily involved short-term Randomized Controlled Trials (RCTs) and systematic reviews. These studies were used in research exploring how symptoms change over time, focusing on outcomes related to physical discomfort and patient-reported outcomes describing perceived discomfort.

The trials monitored subjective symptom score measurements over short-term periods, typically spanning 4 to 7 days. Findings described patterns observed in the studies related to subjective symptom scores, and results were mixed across various analyses. The authoritative regulatory reviews of this evidence indicate that the overall certainty remains low. This is because existing studies were observed in some reviews to have study design limitations and evidence quality varies across studies, complicating the interpretation of results concerning patterns of symptom evolution.


What Remains Uncertain About the Research for Fusaloyos

Authoritative regulatory bodies, after reviewing the evidence base, formally described the evidence concerning study outcomes as weak. This assessment was associated with a combination of factors, including study design limitations, imprecision, and inconsistency of results across the published trials. Furthermore, a lack of adequate modern studies sufficient to support the medicine's efficacy was cited in regulatory findings.

The research exploring short-term symptom changes in cohorts of children (e.g., ages 8–12 years) is limited, and data for certain groups remain insufficient. There is limited information for long-term outcomes, and long-term effects are not fully established. Clinical practice guidelines also generally do not provide recommendations for the use of this medicine based on the existing research landscape.

Frequently Asked Questions (FAQ)

Common questions about Fusaloyos (FAQ)

Q: Is Fusaloyos considered a treatment for a chronic or temporary condition?

Official regulatory documentation specifies that the course of treatment with Fusaloyos is short-term and is generally not intended to last longer than seven days. This duration is consistent with its use for acute (temporary) conditions affecting the upper respiratory tract. The medicine is not designed for ongoing, chronic use.


Q: What is the risk of Fusaloyos interacting with common prescription medicines?

Official documentation states that no formal studies to systematically document potential drug interactions have been performed. However, due to the drug's localized delivery as an aerosol and its limited absorption into the body, the overall potential for clinically significant systemic drug-drug interactions is considered low.


Q: Is Fusaloyos recommended for elderly patients?

The medicine is currently subject to market revocation in several regions, establishing an absolute prohibition for use in the general population. Prior to these regulatory actions, official labeling did not specify the need for a dose adjustment specifically for older adults.


Q: Was Fusaloyos tested in large-scale clinical trials before it was approved?

Regulatory reviews included analyses from several clinical trials, including a pooled analysis of three randomized controlled trials involving hundreds of patients. These studies focused on observing short-term symptomatic improvement over the course of treatment.


Q: What are the proper steps for a person to safely stop taking Fusaloyos?

The official administration protocol describes a treatment period that does not exceed seven days. If a patient does not observe symptomatic improvement after this time, the regulatory documents indicate that the product is officially discontinued.


Q: How long does it typically take for Fusaloyos to reach its full effect?

Clinical trials typically evaluated changes in patient-reported symptoms over the mandated short-term course of treatment. Evaluation points to assess the level of improvement often occurred around Day 4 and Day 7 of the treatment period.


Q: Can Fusaloyos cause dizziness or lightheadedness?

Dizziness or lightheadedness are not listed among the commonly or rarely reported adverse effects documented in the official regulatory product information. The documented side effects primarily relate to local irritation and serious allergic reactions.


Q: Will Fusaloyos affect my ability to drive or operate machinery?

Official documentation directly addresses this concern. The medicine is stated to have no or negligible influence on a person's ability to drive or use machines.


Q: Is weight change mentioned as a possible side effect of Fusaloyos?

According to the official regulatory product information, weight change is not listed as one of the documented adverse effects. Documented effects are generally related to the immune system and the respiratory tract.


Q: Is Fusaloyos only approved for use in men, or can women use it too?

The official labeling does not specify gender as a restriction for use. Clinical studies for the medicine have historically included both male and female participants.


Q: Where can I find published research or evidence for Fusaloyos?

Summaries and findings of the clinical research and evidence considered during the approval process are typically made available through official government sources. These include the regulatory review documents published by agencies such as the European Medicines Agency (EMA).


Q: How do you pronounce 'Fusaloyos' correctly?

The medicine name is a brand name for the active ingredient, Fusafungine. According to pharmacological nomenclature, the active ingredient is pronounced fuse-a-fun-nine.


Q: Is Fusaloyos a narcotic or controlled substance?

Fusaloyos is classified in the category of throat preparations with antimicrobial properties. It is not listed as a narcotic or a controlled substance under official drug scheduling systems.


Q: Why is it necessary to take Fusaloyos with a meal?

The official administration protocol for Fusaloyos does not specify a requirement to take the medicine with a meal. Furthermore, no formal food interaction patterns are documented in the official product information.


Q: Does Fusaloyos carry any warnings related to heart health?

Official warnings and safety documentation primarily focus on the risk of serious allergic reactions, such as bronchospasm (severe airway constriction) and laryngeal spasm (vocal cord spasm). No specific warnings related to heart health are documented.

How should Fusaloyos be stored and disposed of?

How to Store and Dispose of Fusaloyos (Fusafungine Aerosol)

The storage and disposal of Fusaloyos, which is formulated as a pressurized aerosol, must strictly follow regulatory instructions to ensure stability and safety.


Mandatory Storage Conditions

Requirement Official Regulatory Statement
Temperature Store below 25 C or 30 C (ambient temperature).
Prohibited Do not refrigerate or freeze; protect the pressurized container from direct sunlight and extreme heat, specifically above 50 C.
Protection Keep the medicine in its original container and strictly out of the sight and reach of children.

Official Disposal Instructions

Due to its status as a pressurized pharmaceutical container, Fusaloyos requires specific disposal procedures:

  • Unused or expired product must be disposed of through a drug take-back program or designated collection site.
  • The medication must not be thrown into household trash or discarded into the wastewater system (sinks, toilets).

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Fusaloyos found in:

A-Z Index: